来那度胺用于转移性肾细胞癌患者的II期试验。
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
作者信息
Patel Premal H, Kondagunta G Varuni, Schwartz Lawrence, Ishill Nicole, Bacik Jennifer, DeLuca John, Russo Paul, Motzer Robert J
机构信息
Genitourinary Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
出版信息
Invest New Drugs. 2008 Jun;26(3):273-6. doi: 10.1007/s10637-007-9107-y. Epub 2007 Dec 27.
Lenalidomide (CC-5013) is a structural derivative of thalidomide, with antiangiogenic and immunomodulatory effects. Fourteen patients with metastatic renal cell carcinoma (RCC) were enrolled on a phase 2 trial of lenalidomide administered orally at 25 mg daily for 21 days followed by a rest period of 7 days. The best response was stable disease in eight patients (57%) of the 14 evaluable patients. Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial.
来那度胺（CC - 5013）是沙利度胺的结构衍生物，具有抗血管生成和免疫调节作用。14例转移性肾细胞癌（RCC）患者参加了一项来那度胺的2期试验，口服剂量为每日25mg，共21天，随后休息7天。14例可评估患者中，8例（57%）的最佳反应为病情稳定。毒性反应包括疲劳、高血糖、呼吸困难以及骨髓抑制，表现为血红蛋白降低、淋巴细胞减少和中性粒细胞减少。来那度胺耐受性良好，但在该临床试验中未观察到客观缓解。
Zotero 插件